title: Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.
abstract: The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [D-Pen(2,5)]-enkephalin (DPDPE), decreased the potency of [D-Ala(2),D-Leu(5)]-enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide (SNC80) to inhibit prostaglandin E(2) (PGE(2))-stimulated adenylyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE(2)-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5'-guanidinonaltrindole (5'-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included coimmunoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6'-GNTI inhibited adenylyl cyclase activity in vitro as well as PGE(2)-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.
authors.affiliation: Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX 78229, USA. berg@uthscsa.edu
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Berg
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Rowan
authors.forename: Achla
authors.initials: A
authors.lastname: Gupta
authors.forename: Teresa A
authors.initials: TA
authors.lastname: Sanchez
authors.forename: Michelle
authors.initials: M
authors.lastname: Silva
authors.forename: Ivone
authors.initials: I
authors.lastname: Gomes
authors.forename: Blaine A
authors.initials: BA
authors.lastname: McGuire
authors.forename: Philip S
authors.initials: PS
authors.lastname: Portoghese
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Hargreaves
authors.forename: Lakshmi A
authors.initials: LA
authors.lastname: Devi
authors.forename: William P
authors.initials: WP
authors.lastname: Clarke
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D002478:Cells, Cultured; D015195:Drug Design; D006930:Hyperalgesia / Q000209:etiology; D008024:Ligands; D055503:Protein Multimerization; D051381:Rats; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism*; D011984:Sensory Receptor Cells / Q000737:chemistry*
chemical_list: D008024:Ligands; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa
references.citation: Neuropharmacology. 2011 Jan;60(1):24-35
references.pmid: 20637785
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5098-103
references.pmid: 21385944
references.citation: Nat Rev Drug Discov. 2005 Nov;4(11):919-27
references.pmid: 16264435
references.citation: Pain. 2006 Nov;125(1-2):114-24
references.pmid: 16781076
references.citation: J Med Chem. 2004 Jun 3;47(12):2969-72
references.pmid: 15163177
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):839-47
references.pmid: 17347322
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20115-9
references.pmid: 21041644
references.citation: Eur J Pharmacol. 2003 Apr 25;467(1-3):233-4
references.pmid: 12706480
references.citation: J Med Chem. 2001 Jun 21;44(13):2073-9
references.pmid: 11405645
references.citation: Mol Pharmacol. 2005 Jun;67(6):2173-84
references.pmid: 15778451
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):544-52
references.pmid: 17267582
references.citation: J Pharmacol Exp Ther. 2011 Jul;338(1):92-9
references.pmid: 21487072
references.citation: Mol Pharmacol. 2005 Oct;68(4):1079-86
references.pmid: 16006595
references.citation: J Biol Chem. 2003 Jun 27;278(26):23731-7
references.pmid: 12690115
references.citation: J Pharmacol Exp Ther. 2007 Jul;322(1):166-71
references.pmid: 17400888
references.citation: Nat Chem Biol. 2009 Sep;5(9):688-95
references.pmid: 19648932
references.citation: Mol Pharmacol. 1997 Jul;52(1):172-9
references.pmid: 9224827
references.citation: Pain. 1988 Jan;32(1):77-88
references.pmid: 3340425
references.citation: Nature. 1999 Jun 17;399(6737):697-700
references.pmid: 10385123
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9050-5
references.pmid: 15932946
references.citation: Neuroscience. 2007 Feb 9;144(3):889-97
references.pmid: 17157995
references.citation: J Pharmacol Exp Ther. 1989 Mar;248(3):1269-75
references.pmid: 2539460
references.citation: J Neurosci. 2005 Sep 28;25(39):8825-32
references.pmid: 16192372
references.citation: Prostaglandins. 1979 Aug;18(2):191-200
references.pmid: 230543
references.citation: J Recept Signal Transduct Res. 2010 Oct;30(5):272-83
references.pmid: 20684666
references.citation: Pharmacol Rev. 2010 Dec;62(4):701-25
references.pmid: 21079041
references.citation: Eur J Pharmacol. 2009 Jan 14;602(2-3):283-7
references.pmid: 19063879
references.citation: Sci Signal. 2010 Jul 20;3(131):ra54
references.pmid: 20647592
references.citation: Psychopharmacology (Berl). 2010 Jun;210(2):137-47
references.pmid: 20401607
references.citation: Trends Pharmacol Sci. 2009 Sep;30(9):460-9
references.pmid: 19729207